UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 393

Sortiert nach

Alcohol and the Etiology of Depression

The American journal of psychiatry, 2023-03, Vol.180 (3), p.179-181

Nunes, Edward V

2023

Link zum Volltext

Verfügbarkeit prüfen

Zero-Inflated and Hurdle Models of Count Data with Extra Zeros: Examples from an HIV-Risk Reduction Intervention Trial

The American journal of drug and alcohol abuse, 2011-09, Vol.37 (5), p.367-375

2011

Link zum Volltext

Verfügbarkeit prüfen

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

The Lancet (British edition), 2018-01, Vol.391 (10118), p.309-318

2018

Link zum Volltext

Verfügbarkeit prüfen

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial

The Lancet (British edition), 2011, Vol.377 (9776), p.1506-1513

2011

Link zum Volltext

Verfügbarkeit prüfen

The Elephants in the Room: Why Physicians Are Not Prescribing

Psychiatric services (Washington, D.C.), 2022-05, Vol.73 (5), p.481-481

2022

Link zum Volltext

Verfügbarkeit prüfen

Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder

The American journal of psychiatry, 2023-05, Vol.180 (5), p.386

2023

Link zum Volltext

Verfügbarkeit prüfen

Co-occurring Depression and Suicidal Ideation in Opioid Use Disorder: Prevalence and Response During Treatment With Buprenorphine-Naloxone and Injection Naltrexone

The journal of clinical psychiatry, 2022-04, Vol.83 (3)

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder

Psychiatric services (Washington, D.C.), 2023-12, Vol.74 (12), p.1227

2023

Link zum Volltext

Verfügbarkeit prüfen

Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder

Drug and alcohol dependence, 2023-09, Vol.250, p.110899-110899, Article 110899

2023

Link zum Volltext

Verfügbarkeit prüfen

Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment

The American journal of psychiatry, 2021-07, Vol.178 (7), p.660-671

2021

Link zum Volltext

Verfügbarkeit prüfen

Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)"

Addiction science & clinical practice, 2021-03, Vol.16 (1), p.15-15, Article 15

2021

Link zum Volltext

Verfügbarkeit prüfen

A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders

Addiction (Abingdon, England), 2013-06, Vol.108 (6), p.1084-1094

2013

Link zum Volltext

Verfügbarkeit prüfen

Transcranial Magnetic Stimulation of Medial Prefrontal and Cingulate Cortices Reduces Cocaine Self-Administration: A Pilot Study

Frontiers in psychiatry, 2018-03, Vol.9, p.80-80

2018

Link zum Volltext

Verfügbarkeit prüfen

A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial

The American journal of psychiatry, 2020-02, Vol.177 (2), p.125-133

2020

Link zum Volltext

Verfügbarkeit prüfen

Buprenorphine Treatment for Opioid Use Disorder: An Overview

CNS drugs, 2019-06, Vol.33 (6), p.567-580

2019

Link zum Volltext

Verfügbarkeit prüfen

Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone

Drug and alcohol dependence, 2019-12, Vol.205, p.107649-107649, Article 107649

2019

Link zum Volltext

Verfügbarkeit prüfen

Is extended release naltrexone superior to buprenorphine‐naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial

Alcoholism, clinical and experimental research, 2021-12, Vol.45 (12), p.2569-2578

2021

Link zum Volltext

Verfügbarkeit prüfen

Under-representation of key demographic groups in opioid use disorder trials

Drug and alcohol dependence reports, 2022-09, Vol.4, p.100084, Article 100084

2022

Link zum Volltext

Verfügbarkeit prüfen

Development of a Cascade of Care for responding to the opioid epidemic

The American journal of drug and alcohol abuse, 2019-01, Vol.45 (1), p.1-10

2019

Link zum Volltext

Verfügbarkeit prüfen

Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary study

Drug and alcohol dependence reports, 2022-03, Vol.2, p.100016-100016, Article 100016

2022

Link zum Volltext

Verfügbarkeit prüfen

NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale

Contemporary clinical trials, 2016-09, Vol.50, p.253-264

2016

Link zum Volltext

Verfügbarkeit prüfen

Self-Report After Randomly Assigned Supervision Does not Predict Ability to Practice Motivational Interviewing

Journal of substance abuse treatment, 2015-10, Vol.57, p.96-101

2015

Link zum Volltext

Verfügbarkeit prüfen

A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence

Journal of substance abuse treatment, 2014-05, Vol.46 (5), p.546-552

2014

Link zum Volltext

Verfügbarkeit prüfen

Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans

Addiction science & clinical practice, 2022-01, Vol.17 (1), p.6-6, Article 6

2022

Link zum Volltext

Verfügbarkeit prüfen

Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder

Addiction (Abingdon, England), 2019-08, Vol.114 (8), p.1416-1426

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 393

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(352)
Mit Volltextzugriff
(349)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(270)
Humans
(268)
Life Sciences & Biomedicine
(268)
Substance Abuse
(191)
Female
(188)
Male
(181)
Adult
(176)
Psychiatry
(170)
Middle Aged
(100)
Social Sciences
(98)
Substance Abuse Treatment
(93)
Psychology
(91)
Drug Abuse
(85)
Biological And Medical Sciences
(80)
Psychology, Clinical
(80)
Medical Sciences
(79)
Treatment Outcome
(79)
Psychology. Psychoanalysis. Psychiatry
(76)
Psychopathology. Psychiatry
(66)
Drug Addiction
(65)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Alcohol and the Etiology of Depression

Zero-Inflated and Hurdle Models of Count Data with Extra Zeros: Examples from an HIV-Risk Reduction Intervention Trial

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial

The Elephants in the Room: Why Physicians Are Not Prescribing

Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder

Co-occurring Depression and Suicidal Ideation in Opioid Use Disorder: Prevalence and Response During Treatment With Buprenorphine-Naloxone and Injection Naltrexone

Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder

Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder

Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment

Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)"

A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders

Transcranial Magnetic Stimulation of Medial Prefrontal and Cingulate Cortices Reduces Cocaine Self-Administration: A Pilot Study

A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial

Buprenorphine Treatment for Opioid Use Disorder: An Overview

Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone

Is extended release naltrexone superior to buprenorphine‐naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial

Under-representation of key demographic groups in opioid use disorder trials

Development of a Cascade of Care for responding to the opioid epidemic

Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary study

NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale

Self-Report After Randomly Assigned Supervision Does not Predict Ability to Practice Motivational Interviewing

A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence

Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans

Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder

Suchergebnisse filtern